文献速递认知障碍与痴呆

阿尔茨海默病脑萎缩亚型与认知及衰退速率相关

Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
PubMed 文献 · Neurology · 2017-10-25

本研究基于ADNI队列中229例 amyloid 阳性AD患者(100例有2年随访),用体积MRI测量皮层和海马体积,按类似tau病理的算法定义亚型。海马保留型(HpSpMRI)基线执行功能更差且后续临床衰退更快,海马体积与皮层体积比(HV:CTV)增大预测更快的临床衰退。

要点

  • vMRI可识别与tau病理表型一致的AD亚型。
  • HpSpMRI亚型基线执行功能差,后续衰退更快。
  • HV:CTV比值增大预测更快的临床衰退。

核心结论

  • AD亚型可在体内通过vMRI识别,表型与tau神经病理一致。
  • HV:CTV比值增大预测AD患者更快的临床衰退。

研究设计与样本

  • 纳入ADNI1和ADNI2中amyloid阳性的AD患者,基线MRI共229例,2年临床随访100例。
  • 按类似tau神经病理的算法定义海马保留型(HpSpMRI)、边缘优势型(LPMRI)和典型AD(tADMRI)亚型。

主要发现

  • HpSpMRI组较其他组18F-FDG-PET显示更多AD样低代谢(p<0.05),基线执行功能更差(p<0.001)。
  • HpSpMRI组较LPMRI组在ADAS-Cog13、MMSE和FAQ上后续临床衰退更快(均p<0.05)。
  • HpSpMRI组较tADMRI组在MMSE和CDR-SB上衰退更快(均p<0.05)。
  • HV:CTV比值较大与基线执行功能较差及CDR-SB、MMSE、ADAS-Cog13下降斜率更快相关(p<0.05)。
  • 上述关联主要由皮层萎缩程度而非海马萎缩程度驱动。

临床怎么用

  • 临床可借助vMRI评估AD患者脑萎缩亚型,识别海马保留型以预判更快的认知衰退。
  • HV:CTV比值可作为预测AD临床进展速度的影像学指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the hypothesis that cortical and hippocampal volumes, measured in vivo from volumetric MRI (vMRI) scans, could be used to identify variant subtypes of Alzheimer disease (AD) and to prospectively predict the rate of clinical decline. METHODS: Amyloid-positive participants with AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI) 1 and ADNI2 with baseline MRI scans (n = 229) and 2-year clinical follow-up (n = 100) were included. AD subtypes (hippocampal sparing [HpSpMRI], limbic predominant [LPMRI], typical AD [tADMRI]) were defined according to an algorithm analogous to one recently proposed for tau neuropathology. Relationships between baseline hippocampal volume to cortical volume ratio (HV:CTV) and clinical variables were examined by both continuous regression and categorical models. RESULTS: When participants were divided categorically, the HpSpMRI group showed significantly more AD-like hypometabolism on 18F-fluorodeoxyglucose-PET (p < 0.05) and poorer baseline executive function (p < 0.001). Other baseline clinical measures did not differ across the 3 groups. Participants with HpSpMRI also showed faster subsequent clinical decline than participants with LPMRI on the Alzheimer's Disease Assessment Scale, 13-Item Subscale (ADAS-Cog13), Mini-Mental State Examination (MMSE), and Functional Assessment Questionnaire (all p < 0.05) and tADMRI on the MMSE and Clinical Dementia Rating Sum of Boxes (CDR-SB) (both p < 0.05). Finally, a larger HV:CTV was associated with poorer baseline executive function and a faster slope of decline in CDR-SB, MMSE, and ADAS-Cog13 score (p < 0.05). These associations were driven mostly by the amount of cortical rather than hippocampal atrophy. CONCLUSIONS: AD subtypes with phenotypes consistent with those observed with tau neuropathology can be identified in vivo with vMRI. An increased HV:CTV ratio was predictive of faster clinical decline in participants with AD who were clinically indistinguishable at baseline except for a greater dysexecutive presentation.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Risacher SL, Anderson WH, Charil A, et al. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology. 2017. PMID: 29070667. doi:10.1212/WNL.0000000000004670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。